Molecular Analysis and Modeling of Hepatitis E Virus Helicase and Identification of Novel Inhibitors by Virtual Screening

The hepatitis E virus- (HEV-) helicase as a novel drug-target was evaluated. While cell culture model was used for mutational characterization of helicase, in silico protein modeling and virtual screening were employed to identify helicase inhibitors. None of the saturation mutant replicons signific...

Full description

Bibliographic Details
Main Authors: Mohammad K. Parvez, Naidu Subbarao
Format: Article
Language:English
Published: Hindawi Limited 2018-01-01
Series:BioMed Research International
Online Access:http://dx.doi.org/10.1155/2018/5753804
id doaj-c43e853e4c3e4663aac5d6937777d150
record_format Article
spelling doaj-c43e853e4c3e4663aac5d6937777d1502020-11-24T22:26:33ZengHindawi LimitedBioMed Research International2314-61332314-61412018-01-01201810.1155/2018/57538045753804Molecular Analysis and Modeling of Hepatitis E Virus Helicase and Identification of Novel Inhibitors by Virtual ScreeningMohammad K. Parvez0Naidu Subbarao1Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Saudi ArabiaSchool of Computational and Integrative Sciences, Jawaharlal Nehru University, New Delhi, IndiaThe hepatitis E virus- (HEV-) helicase as a novel drug-target was evaluated. While cell culture model was used for mutational characterization of helicase, in silico protein modeling and virtual screening were employed to identify helicase inhibitors. None of the saturation mutant replicons significantly affected RNA replication. Notably, mutants encompassing the Walker motifs replicated as wild-type, showing indispensability of nucleotides conservation in viability compared to known criticality of amino acids. A 3D modeling of HEV-helicase and screening of a compound dataset identified ten most promising inhibitors with drug likeness, notably, JFD02650, RDR03130, and HTS11136 that interacted with Walker A residues Gly975, Gly978, Ser979, and Gly980. Our model building and virtual identification of novel helicase inhibitors warrant further studies towards developing anti-HEV drugs.http://dx.doi.org/10.1155/2018/5753804
collection DOAJ
language English
format Article
sources DOAJ
author Mohammad K. Parvez
Naidu Subbarao
spellingShingle Mohammad K. Parvez
Naidu Subbarao
Molecular Analysis and Modeling of Hepatitis E Virus Helicase and Identification of Novel Inhibitors by Virtual Screening
BioMed Research International
author_facet Mohammad K. Parvez
Naidu Subbarao
author_sort Mohammad K. Parvez
title Molecular Analysis and Modeling of Hepatitis E Virus Helicase and Identification of Novel Inhibitors by Virtual Screening
title_short Molecular Analysis and Modeling of Hepatitis E Virus Helicase and Identification of Novel Inhibitors by Virtual Screening
title_full Molecular Analysis and Modeling of Hepatitis E Virus Helicase and Identification of Novel Inhibitors by Virtual Screening
title_fullStr Molecular Analysis and Modeling of Hepatitis E Virus Helicase and Identification of Novel Inhibitors by Virtual Screening
title_full_unstemmed Molecular Analysis and Modeling of Hepatitis E Virus Helicase and Identification of Novel Inhibitors by Virtual Screening
title_sort molecular analysis and modeling of hepatitis e virus helicase and identification of novel inhibitors by virtual screening
publisher Hindawi Limited
series BioMed Research International
issn 2314-6133
2314-6141
publishDate 2018-01-01
description The hepatitis E virus- (HEV-) helicase as a novel drug-target was evaluated. While cell culture model was used for mutational characterization of helicase, in silico protein modeling and virtual screening were employed to identify helicase inhibitors. None of the saturation mutant replicons significantly affected RNA replication. Notably, mutants encompassing the Walker motifs replicated as wild-type, showing indispensability of nucleotides conservation in viability compared to known criticality of amino acids. A 3D modeling of HEV-helicase and screening of a compound dataset identified ten most promising inhibitors with drug likeness, notably, JFD02650, RDR03130, and HTS11136 that interacted with Walker A residues Gly975, Gly978, Ser979, and Gly980. Our model building and virtual identification of novel helicase inhibitors warrant further studies towards developing anti-HEV drugs.
url http://dx.doi.org/10.1155/2018/5753804
work_keys_str_mv AT mohammadkparvez molecularanalysisandmodelingofhepatitisevirushelicaseandidentificationofnovelinhibitorsbyvirtualscreening
AT naidusubbarao molecularanalysisandmodelingofhepatitisevirushelicaseandidentificationofnovelinhibitorsbyvirtualscreening
_version_ 1725753036721094656